A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
Clinical trial NCT07650916 · RECRUITING
Trial details
- NCT number
- NCT07650916
- Sponsor
- ViiV Healthcare
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-25
- Primary completion
- 2029-09-04
- Enrollment
- 564
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.